-

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November:

Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Tuesday, November 11, 2025
Time: 12:30 p.m. ET

Stifel 2025 Healthcare Conference
Date: Wednesday, November 12, 2025
Time: 2:00 p.m. ET

Jefferies Global Healthcare Conference in London
Date: Tuesday, November 18, 2025
Time: 8:30 a.m. GMT / 3:30 a.m. ET

A live webcast of these events can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.

About enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

To learn more, please visit enGene.com and follow us on LinkedIn, X and BlueSky.

Contacts

For media contact:
media@engene.com

For investor contact:
investors@engene.com

Industry:

enGene Holdings Inc.

NASDAQ:ENGN
Release Versions
English

Contacts

For media contact:
media@engene.com

For investor contact:
investors@engene.com

More News From enGene Holdings Inc.

enGene Named a BioSpace 2026 Best Places to Work Winner

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the company to its 2026 Best Places to Work. enGene is among 50 U.S. operating employers recognized as one of the most desirable workplaces in the life sciences industry. “Recognition as a BioSpace Best Place to Work honors enGene’s commitment to create a positive work environment, underpinned by our m...

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists of a non-qualified stock option to purchase an aggregate 600,000 of the Company's common shares. The inducement aw...

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regulatory submissions, and medical affairs. He mos...
Back to Newsroom